NAS:LNTH (USA) Also trade in: Germany

Lantheus Holdings Inc

$ 26.45 -0.05 (-0.19%)
Volume: 227,168 Avg Vol (1m): 371,910
Market Cap $: 1.03 Bil Enterprise Value $: 1.18 Bil
P/E (TTM): 24.49 P/B: 12.72
Earnings Power Value 18.04
Net Current Asset Value -4.15
Tangible Book 1.48
Projected FCF 6.2
Median P/S Value 13.96
Graham Number 5.99
Peter Lynch Value 11.93
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 5/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt 0.42
Cash-To-Debt ranked lower than
83.52% of 261 companies
in the Diagnostics & Research industry.
Industry Max: 32990, Med: 3.52, Min: 0.01
LNTH: 0.42
Ranked among companies with meaningful Cash-To-Debt only.
Cash-To-Debt range over the past 10 years
Min: 0.04, Med: 0.15, Max: 0.43
Current: 0.42
0.04
0.43
Equity-to-Asset 0.19
Equity-to-Asset ranked lower than
94.98% of 239 companies
in the Diagnostics & Research industry.
Industry Max: 0.97, Med: 0.61, Min: -2.81
LNTH: 0.19
Ranked among companies with meaningful Equity-to-Asset only.
Equity-to-Asset range over the past 10 years
Min: -0.98, Med: -0.56, Max: 0.19
Current: 0.19
-0.98
0.19
Debt-to-Equity 3.20
Debt-to-Equity ranked lower than
99.39% of 164 companies
in the Diagnostics & Research industry.
Industry Max: 22.86, Med: 0.36, Min: 0.01
LNTH: 3.2
Ranked among companies with meaningful Debt-to-Equity only.
Debt-to-Equity range over the past 10 years
Min: -3.44, Med: -1.74, Max: 11.51
Current: 3.2
-3.44
11.51
Debt-to-EBITDA 3.25
Debt-to-EBITDA ranked lower than
72.41% of 116 companies
in the Diagnostics & Research industry.
Industry Max: 77.72, Med: 1.77, Min: 0.03
LNTH: 3.25
Ranked among companies with meaningful Debt-to-EBITDA only.
Debt-to-EBITDA range over the past 10 years
Min: 3.25, Med: 6.8, Max: 49.9
Current: 3.25
3.25
49.9
Interest Coverage 3.70
Interest Coverage ranked lower than
90.80% of 163 companies
in the Diagnostics & Research industry.
Industry Max: 15605.52, Med: 76.01, Min: 0.54
LNTH: 3.7
Ranked among companies with meaningful Interest Coverage only.
Interest Coverage range over the past 10 years
Min: 0.93, Med: 1.89, Max: 3.71
Current: 3.7
0.93
3.71
Piotroski F-Score 6
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 2.81
DISTRESS
GREY
SAFE
Beneish M-Score -2.84
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC 24.6%
WACC 12.39%

Profitability & Growth : 5/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % 19.10
Operating Margin ranked higher than
83.88% of 242 companies
in the Diagnostics & Research industry.
Industry Max: 53.36, Med: -0.59, Min: -70300
LNTH: 19.1
Ranked among companies with meaningful Operating Margin only.
Operating Margin range over the past 10 years
Min: -12.27, Med: 13.78, Max: 19.1
Current: 19.1
-12.27
19.1
Net Margin % 12.17
Net Margin ranked higher than
99.17% of 241 companies
in the Diagnostics & Research industry.
Industry Max: 41.13, Med: -2.48, Min: -119600
LNTH: 12.17
Ranked among companies with meaningful Net Margin only.
Net Margin range over the past 10 years
Min: -38.52, Med: -3.1, Max: 37.23
Current: 12.17
-38.52
37.23
ROE % 73.38
ROE ranked lower than
100.00% of 242 companies
in the Diagnostics & Research industry.
Industry Max: 61.7, Med: -6.75, Min: -12038.19
LNTH: 73.38
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: 73.38, Med: 85.94, Max: 85.94
Current: 73.38
73.38
85.94
ROA % 10.05
ROA ranked higher than
98.47% of 262 companies
in the Diagnostics & Research industry.
Industry Max: 1174.65, Med: -4.54, Min: -1248.4
LNTH: 10.05
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: -25.87, Med: -1.41, Max: 38.57
Current: 10.05
-25.87
38.57
ROC (Joel Greenblatt) % 48.53
ROC (Joel Greenblatt) ranked higher than
84.94% of 259 companies
in the Diagnostics & Research industry.
Industry Max: 17601.65, Med: -9.57, Min: -3842027.78
LNTH: 48.53
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: -15.57, Med: 35.12, Max: 51.41
Current: 48.53
-15.57
51.41
3-Year Total Revenue Growth Rate 5.40
3-Year Revenue Growth Rate ranked lower than
71.98% of 182 companies
in the Diagnostics & Research industry.
Industry Max: 371, Med: 4.8, Min: -100
LNTH: -10.2
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
3-Year Revenue Growth Rate range over the past 10 years
Min: -10.2, Med: -5.4, Max: 6.8
Current: -10.2
-10.2
6.8
3-Year Total EBITDA Growth Rate 20.20
3-Year EBITDA Growth Rate ranked lower than
67.42% of 178 companies
in the Diagnostics & Research industry.
Industry Max: 141.7, Med: 10.1, Min: -340.1
LNTH: 2.4
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
3-Year EBITDA Growth Rate range over the past 10 years
Min: -0.5, Med: 27.5, Max: 100.3
Current: 2.4
-0.5
100.3

» LNTH's 30-Y Financials

Financials (Next Earnings Date: 2019-08-01)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:LNTH

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Medical Diagnostics & Research » Diagnostics & Research    NAICS : 621511    SIC : 8071
Compare NAS:FLDM NAS:NRC SHSE:600055 SHSE:603108 SZSE:300685 HKSE:01763 NAS:AXDX NAS:PACB OSTO:CEVI SHSE:603127 TSE:4282 SZSE:300439 SZSE:300396 NAS:CDNA NAS:TWST LSE:IDHC TSE:4694 XBRU:BCART SZSE:300406 NAS:NTRA
Traded in other countries 0L8.Germany
Address 331 Treble Cove Road, North Billerica, MA, USA, 01862
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its imaging products and agents assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. Its agents are typically non-radioactive compounds that are used in diagnostic procedures, such as cardiac ultrasounds, or echocardiograms, x-ray imaging used by physicians to progress the clarity of the diagnostic image. The company's portfolio of imaging products includes medical radiopharmaceuticals such as DEFINITY, TechneLite, Xenon Xe 133 Gas, Cardiolite, and Neurolite. Its revenue is generated from the sales of diagnostic imaging agents to wholesalers, distributors radiopharmacies and directly to hospitals and clinics predominantly in the United States.

Ratios

Current vs industry vs history
PE Ratio (TTM) 24.49
PE Ratio ranked higher than
97.35% of 113 companies
in the Diagnostics & Research industry.
Industry Max: 1345, Med: 35, Min: 0.33
LNTH: 24.49
Ranked among companies with meaningful PE Ratio only.
PE Ratio range over the past 10 years
Min: 2.48, Med: 10.54, Max: 28.02
Current: 24.49
2.48
28.02
Forward PE Ratio 22.62
Forward P/E ranked higher than
87.50% of 40 companies
in the Diagnostics & Research industry.
Industry Max: 78.74, Med: 9999, Min: 11.64
LNTH: 22.62
Ranked among companies with meaningful Forward P/E only.
N/A
PE Ratio without NRI 24.49
PE without NRI ranked higher than
97.35% of 113 companies
in the Diagnostics & Research industry.
Industry Max: 1345, Med: 35.56, Min: 0.34
LNTH: 24.49
Ranked among companies with meaningful PE without NRI only.
PE without NRI range over the past 10 years
Min: 2.48, Med: 10.54, Max: 28.02
Current: 24.49
2.48
28.02
Price-to-Owner-Earnings 23.43
Price-to-Owner-Earnings ranked higher than
98.68% of 76 companies
in the Diagnostics & Research industry.
Industry Max: 1523.53, Med: 36.75, Min: 4.91
LNTH: 23.43
Ranked among companies with meaningful Price-to-Owner-Earnings only.
Price-to-Owner-Earnings range over the past 10 years
Min: 4.07, Med: 7.24, Max: 26.66
Current: 23.43
4.07
26.66
PB Ratio 12.72
PB Ratio ranked lower than
97.55% of 245 companies
in the Diagnostics & Research industry.
Industry Max: 270, Med: 4.02, Min: 0.15
LNTH: 12.72
Ranked among companies with meaningful PB Ratio only.
PB Ratio range over the past 10 years
Min: 8.11, Med: 12.12, Max: 38.25
Current: 12.72
8.11
38.25
PS Ratio 3.01
PS Ratio ranked higher than
73.91% of 230 companies
in the Diagnostics & Research industry.
Industry Max: 6350, Med: 3.81, Min: 0.07
LNTH: 3.01
Ranked among companies with meaningful PS Ratio only.
PS Ratio range over the past 10 years
Min: 0.16, Med: 1.59, Max: 3.06
Current: 3.01
0.16
3.06
Price-to-Free-Cash-Flow 23.79
Price-to-Free-Cash-Flow ranked higher than
81.25% of 80 companies
in the Diagnostics & Research industry.
Industry Max: 1356.19, Med: 29.22, Min: 0.35
LNTH: 23.79
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
Price-to-Free-Cash-Flow range over the past 10 years
Min: 2.25, Med: 16.7, Max: 67.89
Current: 23.79
2.25
67.89
Price-to-Operating-Cash-Flow 14.40
Price-to-Operating-Cash-Flow ranked higher than
82.47% of 97 companies
in the Diagnostics & Research industry.
Industry Max: 1739.7, Med: 19.94, Min: 0.35
LNTH: 14.4
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
Price-to-Operating-Cash-Flow range over the past 10 years
Min: 1.71, Med: 11.45, Max: 581.67
Current: 14.4
1.71
581.67
EV-to-EBIT 17.35
EV-to-EBIT ranked higher than
82.20% of 118 companies
in the Diagnostics & Research industry.
Industry Max: 341.21, Med: 25.06, Min: 5.74
LNTH: 17.35
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: 8.6, Med: 15.9, Max: 37.4
Current: 17.35
8.6
37.4
EV-to-EBITDA 14.46
EV-to-EBITDA ranked higher than
79.55% of 132 companies
in the Diagnostics & Research industry.
Industry Max: 486.47, Med: 20.75, Min: 3.94
LNTH: 14.46
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: 6.3, Med: 10.4, Max: 14.63
Current: 14.46
6.3
14.63
EV-to-Revenue 3.35
EV-to-Revenue ranked higher than
71.90% of 242 companies
in the Diagnostics & Research industry.
Industry Max: 19679, Med: 4.24, Min: 0.09
LNTH: 3.35
Ranked among companies with meaningful EV-to-Revenue only.
EV-to-Revenue range over the past 10 years
Min: 1.2, Med: 2.2, Max: 3.4
Current: 3.35
1.2
3.4
PEG Ratio 0.69
PEG Ratio ranked lower than
100.00% of 48 companies
in the Diagnostics & Research industry.
Industry Max: 128.13, Med: 3.26, Min: 0.32
LNTH: 0.69
Ranked among companies with meaningful PEG Ratio only.
PEG Ratio range over the past 10 years
Min: 0.08, Med: 0.18, Max: 2.18
Current: 0.69
0.08
2.18
Current Ratio 4.57
Current Ratio ranked higher than
59.20% of 250 companies
in the Diagnostics & Research industry.
Industry Max: 97.84, Med: 2.58, Min: 0.02
LNTH: 4.57
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 1.42, Med: 2.73, Max: 4.57
Current: 4.57
1.42
4.57
Quick Ratio 3.82
Quick Ratio ranked higher than
57.60% of 250 companies
in the Diagnostics & Research industry.
Industry Max: 97.84, Med: 2.14, Min: 0.02
LNTH: 3.82
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 1.1, Med: 2.22, Max: 3.82
Current: 3.82
1.1
3.82
Days Inventory 69.83
Days Inventory ranked higher than
65.69% of 204 companies
in the Diagnostics & Research industry.
Industry Max: 917.88, Med: 79.76, Min: 0.37
LNTH: 69.83
Ranked among companies with meaningful Days Inventory only.
Days Inventory range over the past 10 years
Min: 15.47, Med: 36.06, Max: 69.83
Current: 69.83
15.47
69.83
Days Sales Outstanding 47.32
Days Sales Outstanding ranked higher than
73.04% of 204 companies
in the Diagnostics & Research industry.
Industry Max: 521.64, Med: 67.51, Min: 1
LNTH: 47.32
Ranked among companies with meaningful Days Sales Outstanding only.
Days Sales Outstanding range over the past 10 years
Min: 44.34, Med: 46.51, Max: 52.42
Current: 47.32
44.34
52.42
Days Payable 32.78
Days Payable ranked lower than
73.26% of 187 companies
in the Diagnostics & Research industry.
Industry Max: 981.81, Med: 63.34, Min: 1
LNTH: 32.78
Ranked among companies with meaningful Days Payable only.
Days Payable range over the past 10 years
Min: 26.94, Med: 32.48, Max: 42.13
Current: 32.78
26.94
42.13

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -9.20
3-Year Share Buyback Rate ranked lower than
55.56% of 180 companies
in the Diagnostics & Research industry.
Industry Max: 3.4, Med: -7.9, Min: -1732.6
LNTH: -9.2
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
3-Year Share Buyback Rate range over the past 10 years
Min: -9.2, Med: -7.9, Max: 0
Current: -9.2
-9.2
0

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 17.87
Price-to-Tangible-Book ranked lower than
100.00% of 207 companies
in the Diagnostics & Research industry.
Industry Max: 272.36, Med: 6.46, Min: 0.21
LNTH: 17.87
Ranked among companies with meaningful Price-to-Tangible-Book only.
Price-to-Tangible-Book range over the past 10 years
Min: 13.43, Med: 19.12, Max: 88.33
Current: 17.87
13.43
88.33
Price-to-Projected-FCF 4.27
Price-to-Intrinsic-Value-Projected-FCF ranked lower than
100.00% of 75 companies
in the Diagnostics & Research industry.
Industry Max: 449, Med: 2.41, Min: 0.47
LNTH: 4.27
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
Price-to-Intrinsic-Value-Projected-FCF range over the past 10 years
Min: 2.64, Med: 3.14, Max: 4.32
Current: 4.27
2.64
4.32
Price-to-Median-PS-Value 1.89
Price-to-Median-PS-Value ranked lower than
84.46% of 193 companies
in the Diagnostics & Research industry.
Industry Max: 7.22, Med: 1.01, Min: 0.01
LNTH: 1.89
Ranked among companies with meaningful Price-to-Median-PS-Value only.
Price-to-Median-PS-Value range over the past 10 years
Min: 0.11, Med: 0.99, Max: 1.92
Current: 1.89
0.11
1.92
Price-to-Peter-Lynch-Fair-Value 2.22
Price-to-Peter-Lynch-Fair-Value ranked lower than
100.00% of 30 companies
in the Diagnostics & Research industry.
Industry Max: 15.31, Med: 2.01, Min: 0.83
LNTH: 2.22
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
Price-to-Peter-Lynch-Fair-Value range over the past 10 years
Min: 0.18, Med: 0.46, Max: 2.24
Current: 2.22
0.18
2.24
Price-to-Graham-Number 4.42
Price-to-Graham-Number ranked lower than
100.00% of 76 companies
in the Diagnostics & Research industry.
Industry Max: 49.42, Med: 3.98, Min: 0.39
LNTH: 4.42
Ranked among companies with meaningful Price-to-Graham-Number only.
Price-to-Graham-Number range over the past 10 years
Min: 2, Med: 3, Max: 4.47
Current: 4.42
2
4.47
Earnings Yield (Joel Greenblatt) % 5.76
Earnings Yield (Greenblatt) ranked higher than
92.08% of 265 companies
in the Diagnostics & Research industry.
Industry Max: 17.42, Med: -0.98, Min: -1428.57
LNTH: 5.76
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: 2.7, Med: 6.3, Max: 11.6
Current: 5.76
2.7
11.6
Forward Rate of Return (Yacktman) % 13.73
Forward Rate of Return ranked lower than
100.00% of 70 companies
in the Diagnostics & Research industry.
Industry Max: 7802.99, Med: 8.45, Min: -35.9
LNTH: 13.73
Ranked among companies with meaningful Forward Rate of Return only.
Forward Rate of Return range over the past 10 years
Min: 13.6, Med: 23, Max: 24.7
Current: 13.73
13.6
24.7

More Statistics

Revenue (TTM) (Mil) $ 347.25
EPS (TTM) $ 1.08
Beta 1.69
Volatility % 54.31
52-Week Range $ 12.59 - 27.12
Shares Outstanding (Mil) 38.82

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 6
Positive ROA Y
Positive CFROA Y
Higher ROA yoy N
CFROA > ROA Y
Lower Leverage yoy Y
Higher Current Ratio yoy Y
Less Shares Outstanding yoy N
Higher Gross Margin yoy Y
Higher Asset Turnover yoy N